A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the project is to establish a multimodal imaging approach for the investigation of the neural mechanisms underlying neuroreceptor regulation, glutamatergic metabolism and brain function that are of particular relevance for major depressive disorder (MDD) and that can be translated into clinical applications.

There is growing evidence for imbalance with regard to glutamatergic neurotransmission in stress-related affective disorders. Further support for the hypothesis that dysfunctional glutamatergic signaling underlies major depressive disorder, and indeed that its reversal constitutes a potential efficacious mechanism of action, is provided by the evidence that pharmacological compounds active at the N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor such as ketamine exert rapid antidepressant effects. As a tool compound ketamine enables the safe investigation of the brain region-specific effects of NMDA receptor antagonism in terms of glutamatergic neurotransmission, brain function and the association of these neural changes with emotional state, thereby allowing for increased understanding of the therapeutic mechanism of action.

The possibility to simultaneously study brain perfusion (arterial spin labeling), functional brain activity (fMRI) and connectivity (resting state fMRI), neurometabolism (proton magnetic resonance spectroscopy) and metabotropic glutamate receptor densities (positron emission tomography) will unravel their functional interplay in the mechanisms underlying the regulation of mood and cognition. Combining those imaging modalities with treatment interventions in healthy subjects and depressed patients, this project aims at providing insight into the neuropharmacological effects of ketamine and its antidepressant properties.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET Imaging of mGLuR5 With Drug Challenge

NCT01691092

Major Depressive Disorder Post-Traumatic Stress Disorder (PTSD)

COMPLETED NA

Effects of Ketamine on Eye Movements, Perception and Brain Function

NCT02701933

Functional Neuroimaging

COMPLETED NA

Imaging SV2A in Mood Disorders

NCT02734602

Major Depressive Disorder Post-Traumatic Stress Disorder

RECRUITING NA

The Sustained Effects of Ketamine

NCT02708849

Mental Disorders

TERMINATED PHASE1

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

NCT02230592

Anxiety Disorder Major Depressive Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ketamine

i.v. infusion of 0.25 mg/kg S-ketamine over 40 min

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

i.v. infusion of 0.25 mg/kg S-ketamine over 40 min

Placebo

i.v. infusion of NaCl over 40 min

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

i.v. infusion of NaCl over 40 min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ketamine

i.v. infusion of 0.25 mg/kg S-ketamine over 40 min

Intervention Type DRUG

Placebo

i.v. infusion of NaCl over 40 min

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* treatment resistant depressive episode
* no restrictions regarding antidepressant medication

Exclusion Criteria

* lifetime antidepressant treatment with ketamine
* lifetime recreational use of ketamine
* cardiovascular diseases such as hypertonia, cardiac insufficiency or myocardial infarct in the past six months
* insufficiently treated anemia
* hyper- or hypothyroidism
* lifetime increased intracranial pressure or glaucoma
* chronic physical diseases
* hepatorenal dysfunction
* any relevant psychiatric or neurological comorbidity, in particular dementia, epileptic seizures (lifetime), schizophrenia (lifetime), psychosis (lifetime), or post-traumatic stress disorder (current).
* acute suicidality
* substance abuse disorders
* recent heart or head surgery
* metallic body implants
* agoraphobia
* pregnancy
* left handedness

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes